CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages (Q34352560)

1 August 2017

title

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages (English)

1 reference

1 August 2017

K Brøsen

2

0 references

Siegfried Kasper

object named as

S Kasper

5

0 references

author name string

J Kirchheiner

1

1 reference

1 August 2017

M L Dahl

3

1 reference

1 August 2017

L F Gram

4

1 reference

1 August 2017

I Roots

6

1 reference

1 August 2017

F Sjöqvist

7

1 reference

1 August 2017

E Spina

8

1 reference

1 August 2017

J Brockmöller

9

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

Acta Psychiatrica Scandinavica

1 August 2017

published in

1 reference

1 August 2017

volume

104

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

173-192

1 reference

Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Polymorphic hydroxylation of Debrisoquine in man.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Pharmacogenetics of antidepressants: clinical aspects

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Polymorphic cytochromes P450 and drugs used in psychiatry

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Antidepressants and drug-metabolizing enzymes--expert group report

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Metabolism of monoamine oxidase inhibitors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

CYP2C19 genotype and phenotype determined by omeprazole in a Korean population

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Newer antidepressants and the cytochrome P450 system

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

The pharmacogenetics of the selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Drug-drug interactions involving antidepressants: focus on venlafaxine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Differences in interactions of SSRIs

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

1 reference

7 January 2021

Plasma Level Monitoring of Tricyclic Antidepressant Therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Tricyclic antidepressants--blood level measurements and clinical outcome: an APA Task Force report. Task Force on the Use of Laboratory Tests in Psychiatry

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Amitriptyline metabolism: relationship to polymorphic debrisoquine hydroxylation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Amitriptyline metabolism: association with debrisoquin hydroxylation in nonsmokers

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Bupropion plasma levels and CYP2D6 phenotype

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Inhibition of desipramine 2-hydroxylation by quinidine and quinine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Polymorphic 2-hydroxylation of desipramine. A population and family study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Non-linear fluvoxamine disposition

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Imipramine demethylation in vivo: Impact of CYP1A2, CYP2C19, and CYP3A4*

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Inhibitors of imipramine metabolism by human liver microsomes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Steady State Concentrations of the Enantiomers of Mianserin and Desmethylmianserin in Poor and in Homozygous and Heterozygous Extensive Metabolizers of Debrisoquine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

The role of cytochrome P450 2D6 in the metabolism of moclobemide

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study*

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

The relationship between paroxetine and the sparteine oxidation polymorphism

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Metabolic activation of the new tricyclic antidepressant tianeptine by human liver cytochrome P450

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Influence of quinidine on the pharmacokinetics of trimipramine and on its effect on the waking EEG of healthy volunteers. A pilot study on two subjects.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Venlafaxine serum levels and CYP2D6 genotype

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Urinary desipramine hydroxylation index and steady-state plasma concentrations of imipramine and desipramine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Carbamazepine but not valproate induces bupropion metabolism.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Clinical pharmacokinetics of nefazodone

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

The emerging role of cytochrome P450 3A in psychopharmacology

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Antidepressant activity of 2-hydroxydesipramine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Studies on the Stereoselective Metabolism of Citalopram by Human Liver Microsomes and cDNA-Expressed Cytochrome P450 Enzymes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Fluvoxamine-tricyclic antidepressant interaction

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Nonlinear pharmacokinetics of chlorimipramine after infusion and oral administration in patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Imipramine metabolism in relation to the sparteine oxidation polymorphism - a family study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Active metabolites of imipramine and desipramine in man

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs).

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Interethnic dissociation between debrisoquine and desipramine hydroxylation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Importance of oxidative polymorphism on clinical efficacy and side-effects of imipramine--a retrospective study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Isolation and identification of hydroxylated maprotiline metabolites

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Seizures associated with high maprotiline serum concentrations

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Maprotiline treatment in depression. A perspective on seizures

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Clinical pharmacokinetics of mirtazapine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Biotransformation of moclobemide in humans

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Studies on the metabolism and pharmacokinetics of nortriptyline and desmethylimipramine in man

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Disposition of single oral doses of E-10-hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Treatment of depression with E-10-hydroxynortriptyline--a pilot study on biochemical effects and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Comparison of the effects of sertraline and its metabolite desmethylsertraline on blockade of central 5-HT reuptake in vivo.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Trazodone treatment increases plasma prolactin concentrations in depressed patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Inhibition of trazodone metabolism by thioridazine in humans

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Plasma levels of trimipramine and metabolites in four patients: determination of the enantiomer concentrations of the hydroxy metabolites

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Quantitation of trimipramine enantiomers in human serum by enantioselective high-performance liquid chromatography and mixed-mode disc solid-phase extraction

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Determination of trimipramine and metabolites in plasma by liquid chromatography with electrochemical detection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Venlafaxine oxidation in vitro is catalysed by CYP2D6.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2001.00299.X

7 January 2021

10.1034/J.1600-0447.2001.00299.X

Identifiers

DOI

1 reference

release_2yw6vgvh3nfutobivl7v63xr2q

1 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2yw6vgvh3nfutobivl7v63xr2q

24 November 2022

mapped directly with Wikidata item

1 reference